Abstract
The aim of this review is to examine the evidence on the role of antidiabetic agents in patients with type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). In particular, metformin does not seem to have significant effects on liver histology. Glitazones improve steatosis and necro-inflammation, delay progression of fibrosis, and ameliorate glucose and lipid metabolism and subclinical inflammation. However, there is now evidence that prolonged treatment with these agents may offer no additional histological benefit and that metabolic improvement does not necessarily parallel histological improvement. Moreover, the long-term safety and efficacy of glitazones is an issue of continuing concern. Injectable glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors are more recent antidiabetic agents with some promising preliminary resulst in NFLD. However, experience with their use is still very limited. In conclusion, no antidiabetic agent has hitherto been shown to exert a beneficial effect on hepatic fibrosis. However, pharmacological treatment could be considered in patients with non-alcoholic steatohepatitis (NASH) not responding to lifestyle intervention. Finally, larger long-term studies are needed to shed more light on the effect of antidiabetic treatment on NAFLD.
Keywords: Antidiabetic agents, non-alcoholic fatty liver disease, type 2 diabetes mellitus, treatment.
Current Pharmaceutical Design
Title:The Role of Oral Antidiabetic Agents and Incretin Mimetics in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease
Volume: 20 Issue: 22
Author(s): Ioanna Gouni-Berthold, Nikolaos Papanas and Efstratios Maltezos
Affiliation:
Keywords: Antidiabetic agents, non-alcoholic fatty liver disease, type 2 diabetes mellitus, treatment.
Abstract: The aim of this review is to examine the evidence on the role of antidiabetic agents in patients with type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). In particular, metformin does not seem to have significant effects on liver histology. Glitazones improve steatosis and necro-inflammation, delay progression of fibrosis, and ameliorate glucose and lipid metabolism and subclinical inflammation. However, there is now evidence that prolonged treatment with these agents may offer no additional histological benefit and that metabolic improvement does not necessarily parallel histological improvement. Moreover, the long-term safety and efficacy of glitazones is an issue of continuing concern. Injectable glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors are more recent antidiabetic agents with some promising preliminary resulst in NFLD. However, experience with their use is still very limited. In conclusion, no antidiabetic agent has hitherto been shown to exert a beneficial effect on hepatic fibrosis. However, pharmacological treatment could be considered in patients with non-alcoholic steatohepatitis (NASH) not responding to lifestyle intervention. Finally, larger long-term studies are needed to shed more light on the effect of antidiabetic treatment on NAFLD.
Export Options
About this article
Cite this article as:
Gouni-Berthold Ioanna, Papanas Nikolaos and Maltezos Efstratios, The Role of Oral Antidiabetic Agents and Incretin Mimetics in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease, Current Pharmaceutical Design 2014; 20 (22) . https://dx.doi.org/10.2174/13816128113196660676
DOI https://dx.doi.org/10.2174/13816128113196660676 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer’s Disease and Amnestic Mild Cognitive Impairment
Current Alzheimer Research Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs A Medicinal Mushroom: Phellinus Linteus
Current Medicinal Chemistry Role of Endogenous Androgen Against Insulin Resistance and Athero-sclerosis in Men with Type 2 Diabetes
Current Diabetes Reviews Hyper-Coagulable Profile with Elevated Pro-Thrombotic Biomarkers and Increased Cerebro- and Cardio-Vascular Disease Risk Exist Among Healthy Dyslipidemic Women
Current Neurovascular Research CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Functional Domains of Aquaporin-1: Keys to Physiology, and Targets for Drug Discovery
Current Pharmaceutical Design The Current View on the Helicase Activity of RNA Helicase A and Its Role in Gene Expression
Current Protein & Peptide Science Deep Eutectic Solvent (DES) Mediated Multicomponent Synthesis of 4- thiazolidinone-5-carboxylic Acid: A Green Chemistry Approach
Current Catalysis Drug Delivery Systems for Dental Applications
Current Organic Chemistry Risk Factors for Cardiovascular Disease in Psoriasis: Relation to Inflammation Assessed by the Severity and Duration of Illness
Inflammation & Allergy - Drug Targets (Discontinued) Epithelial Cell Signaling in Helicobacter pylori Infection
Current Signal Transduction Therapy Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Association of DRD2 TaqIA and DβH -1021C>T Gene Polymorphisms with Smoking Initiation and their Interaction with Serotonergic System Gene Polymorphisms
Current Pharmacogenomics and Personalized Medicine Endothelial Dysfunction in Sepsis
Current Vascular Pharmacology The Role of Antiplatelet Therapy in Primary Prevention. A Review
Current Pharmaceutical Design Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Repetitive Transcranial Magnetic Stimulation to Treat Substance Use Disorders and Compulsive Behavior
CNS & Neurological Disorders - Drug Targets Strategies for Novel Therapeutic Approaches Targeting Cytokines and Signaling Pathways of Osteoclasto- and Osteoblastogenesis in the Fight Against Immune-Mediated Bone and Joint Diseases
Current Medicinal Chemistry